Email this article Peptidoglycan of plant origin with immunomodulatory activity in therapy of vitiligo
- Authors: Korobko I.V1,2, Lomonosov K.M.3
-
Affiliations:
- VR Foundation Ins
- Institute of Gene Biology
- I.M. Setchenov First Moscow State Medical University
- Issue: Vol 18, No 4 (2015)
- Pages: 44-46
- Section: Articles
- URL: https://journals.rcsi.science/1560-9588/article/view/36993
- DOI: https://doi.org/10.17816/dv36993
- ID: 36993
Cite item
Full Text
Abstract
Vitiligo is now regarded as mainly an autoimmune disease, and hence, use of drugs with immunomodulatory activity is a rational approach to arresting the progress of vitiligo. We study the efficiency of acid peptidoglycan ofplant origin with immunomodulatory activity in therapy of vitiligo. Twenty-five patients with active vitiligo received a course of treatment (6 injections). The activity of vitiligo was evaluated after 1, 3, and 6 months of the therapeutic course. The results were compared with the patients’ clinical and immunological data before therapy. Disease stabilization was attained 6 months after therapy in 18 (72%) patients. Low secretion of phytohemagglutinin-induced IFN-g by peripheral blood mononuclears before therapy seemed to be a prognostic factor predicting active course of vitiligo after therapy (p=0,0022, odds ratio 14,5; 95% confidence interval 3,15-5,72). Hence, use of acid peptidoglycan with immunomodulatory activity can be regarded as a new safe and effective method for vitiligo progress.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
I. V Korobko
VR Foundation Ins; Institute of Gene Biologyдоктор биол. наук, главный научный дир. VR Foundation, Inc., зам. дир. по научной работе Института биологии гена РАН 119334, Moscow, Russia
Konstantin M. Lomonosov
I.M. Setchenov First Moscow State Medical University
Email: lamсlinic@yandex.ru
MD, PhD, DSc, prof. 119991, Moscow, Russia
References
- Laddha N.C., Dwivedi M., Mansuri M.S., Gani A.R., Ansarullah M., Ramachandran A.V., et al. Vitiligo: interplay between oxidative stress and immune system. Exp. Dermatol. 2013; 22(4): 245-50.
- Richmond J.M., Frisoli M.L., Harris J.E. Innate immune mechanisms in vitiligo: danger from within. Curr. Opin. Immunol. 2013; 25(6): 676-82.
- Halliday G.M., Damian D.L., Rana S., Byrne S.N. The suppressive effects of ultraviolet radiation on immunity in the skin and internal organs: implications for autoimmunity. J. Dermatol. Sci. 2012; 66(3): 176-82.
- Bhatnagar A., Kanwar A.J., Parsad D., De D. Psoralen and ultraviolet A and narrow-band ultraviolet B in inducing stability in vitiligo, assessed by vitiligo disease activity score: an open prospective comparative study. J. Eur. Acad. Dermatol. Venereol. 2007; 21(10): 1381-5.
- Kanwar A.J., Mahajan R., Parsad D. Low-dose oral mini-pulse dexamethasone therapy in progressive unstable vitiligo. J. Cutan. Med. Surg. 2013; 17(4): 259-68.
- Szczurko O., Shear N., Taddio A., Boon H. Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial. BMC Complement. Altern. Med. 2011; 11: 21. doi: 10.1186/1472-6882-11-21.
- Parsad D., Pandhi R., Juneja A. Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin. Exp. Dermatol. 2003; 28(3): 285-7.
- Singh A., Kanwar A.J., Parsad D., Mahajan R. Randomized controlled study to evaluate the effectiveness of dexamethasone oral minipulse therapy versus oral minocycline in patients with active vitiligo vulgaris. Indian J. Dermatol. Venereol. Leprol. 2014; 80(1): 29-35.
- Parsad D., Kanwar A. Oral minocycline in the treatment of vitiligo - preliminary study. Dermatol. Ther. 2010; 23(3): 305-7.
- Pasricha J.S., Khera V. Effect of prolonged treatment with levamisole on vitiligo with limited and slow-spreading disease. Int. J. Dermatol. 1994; 33(8): 584-7.
- Awad S.S. Leflunomide is a possible deactivator for vitiligo, a pilot study. J. Eur. Acad. Dermatol. Venereol. 2012; 26(9): 1173. doi: 10.1111/j.1468-3083.2011.04311.x
- Korobko I.V., Lomonosov K.M. Acridone acetic acid, sodium salt, as an agent to stop vitiligo progression: a pilot study. Dermatol. Ther. 2014; 27(4): 219-22.
- Diamond B.J., Bailey M. Ginkgo biloba: indications, mechanisms, and safety. Psychiatr. Clin. North Am. 2013; 36(1): 73-83.
- Hartmann A., Löhberg L., Keikavoussi P., Eichner S., Schuler G. Treatment of generalised vitiligo with tacrolimus 0.1% ointment vs. UVB intense pulsed light phototherapy: a pilot study. Acta Derm. Venereol. 2014; 94(5): 585-7.
- Lotti T., D’Erme A.M. Vitiligo as a systemic disease. Clin. Dermatol. 2014; 32(3): 430-4.
